白蛋白结合型紫杉醇用于晚期胃癌二线治疗的疗效和安全性  

The efficacy and safety of Nab-paclitaxel(Nab-P)on patients with advanced gastric cancer who failed to first-line chemotherapy

作　　者：张玲 朱华云[2] 石永康 ZHNAG Ling;ZHU Huayun;SHI Yongkang(Department of Oncology,Affiliated Jintan Hospital of Jiangsu University Changzhou 213200,China;Department of Oncology,Jiangsu Tumor Hospital,Nanjing 210009,China)

机构地区：[1]常州市金坛区人民医院肿瘤内科,江苏常州213200 [2]江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《常州实用医学》2018年第1期15-18,共4页Changzhou Practical Medicinne

摘　　要：目的分析白蛋白结合型紫杉醇联合化疗治疗一线方案失败晚期胃癌的疗效和安全性。方法对21例晚期胃癌接受一线化疗失败患者采用白蛋白结合型紫杉醇联合方案进行二线治疗,治疗至疾病进展或不可耐受化疗。化疗2个周期后根据RECIST标准评价近期疗效,按照NCICTC3.0标准评价不良反应。结果21例均可评价疗效,无完全缓解患者,部分缓解8例,病情稳定6例,疾病进展7例,有效率为38%,疾病控制率为66%。中位无进展生存时间为6.24个月。16例存活,4例死亡。治疗相关主要不良反应为脱发、骨髓抑制及周围神经毒性,均在可耐受范围内。结论白蛋白结合型紫杉醇联方案治疗晚期一线治疗失败后的胃癌有一定疗效,不良反应可耐受。Objective To evaluate the efficacy and safety of Nab-paclitaxel(Nab-P)on patients with advanced gastric cancer who failed to first-line chemotherapy.Methods The second line chemotherapy with a Nab-P-based monotherapy or combination regimens was performed in 21 patients with advanced gastric cancer,who received rescue chemotherapy after relapse and metastasis.Treatment to disease progression or non-tolerance chemotherapyThe efficacy and safety were evaluated by RECIST and NCI-CTC 3.0 criteria after 2complete cycles of treatment.Results Twenty-one patients after the second line chemotherapy,8 cases showed partial remission(PR),6 cases stable disease(SD),7 cases progress disease(PD).The responsive rate(RR)was 38%,disease control rate(DCR)was 66%,and time to progress(TTP)was 6.24 months.16 survived and 4 died.The common treatment related adverse events werebadlness,bone marrow suppression and neurotoxicity,but they were tolerable.Conclusion Nab-P-based monotherapy or combination regimens is effective and tolerable in advanced gastric cancerwho failed to first-line chemotherapy.The adverse effects were mild and tolerable.

关 键 词：白蛋白结合型紫杉醇 晚期胃癌 疗效 安全性 不良反应 

分 类 号：R735[医药卫生—肿瘤]